Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib

Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib

We characterised changes in absolute lymphocyte counts (ALCs) and lymphocyte subset counts (LSCs), and their relationship to incidence of serious infection events (SIEs) and herpes zoster (HZ) events in Japanese patients with moderate to severe rheumatoid arthritis enrolled in the tofacitinib clinic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Modern rheumatology 2024-10, Vol.34 (6), p.1115-1124
Hauptverfasser: Tanaka, Yoshiya, Takeuchi, Tsutomu, Valdez, Hernan, Collinge, Mark, Zwillich, Samuel H, Toyoizumi, Shigeyuki, Kwok, Kenneth, Hirose, Tomohiro
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1124
container_issue 6
container_start_page 1115
container_title Modern rheumatology
container_volume 34
creator Tanaka, Yoshiya
Takeuchi, Tsutomu
Valdez, Hernan
Collinge, Mark
Zwillich, Samuel H
Toyoizumi, Shigeyuki
Kwok, Kenneth
Hirose, Tomohiro
description We characterised changes in absolute lymphocyte counts (ALCs) and lymphocyte subset counts (LSCs), and their relationship to incidence of serious infection events (SIEs) and herpes zoster (HZ) events in Japanese patients with moderate to severe rheumatoid arthritis enrolled in the tofacitinib clinical programme. Data included 765 patients receiving tofacitinib in Phase 2, Phase 3, and long-term extension studies. ALCs/LSCs and incidence rates (patients with events/100 patient-years) of SIEs and HZ were analysed over 75 months. Median ALCs were generally stable over 75 months of treatment. Transient numerical increases from baseline in median LSCs were observed at Month 3; LSCs were generally lower than baseline for Months 36-75. SIE/HZ incidence rates were higher in patients with ALC
doi_str_mv 10.1093/mr/roae030
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3061139240</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3061139240</sourcerecordid><originalsourceid>FETCH-LOGICAL-c212t-269902cc7f72951d2f51e0739f1bb222a8607b1ce7c1a00a2e30f784a42150b73</originalsourceid><addsrcrecordid>eNo9kE1LxDAQhoMoun5c_AGSowirk6TdNEdZ_GRBED2XNJ3QaNvUJGXZi7_dyq6e5oV55mV4CDlncM1AiZsu3ASvEQTskRnLhJrLBaj9v5yr_Igcx_gBIHJVqENyJIoCmIRsRr5fsdXJ-T42bqAVpjViT9tNNzTebBJS48c-Ud3XNLj4Sb2lrrdofk-mRJ_1oHuMSEODY6eTdzXVITXBJRfpMFVjnyJNAXXCmq5damjyVptp37vqlBxY3UY8280T8n5_97Z8nK9eHp6Wt6u54YynOV8oBdwYaSVXOau5zRmCFMqyquKc62IBsmIGpWEaQHMUYGWR6YyzHCopTsjltncI_mvEmMrORYNtOz3vx1gKWDAmFM9gQq-2qAk-xoC2HILrdNiUDMpf32UXyp3vCb7Y9Y5Vh_U_-idY_ACDzX7i</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3061139240</pqid></control><display><type>article</type><title>Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Tanaka, Yoshiya ; Takeuchi, Tsutomu ; Valdez, Hernan ; Collinge, Mark ; Zwillich, Samuel H ; Toyoizumi, Shigeyuki ; Kwok, Kenneth ; Hirose, Tomohiro</creator><creatorcontrib>Tanaka, Yoshiya ; Takeuchi, Tsutomu ; Valdez, Hernan ; Collinge, Mark ; Zwillich, Samuel H ; Toyoizumi, Shigeyuki ; Kwok, Kenneth ; Hirose, Tomohiro</creatorcontrib><description>We characterised changes in absolute lymphocyte counts (ALCs) and lymphocyte subset counts (LSCs), and their relationship to incidence of serious infection events (SIEs) and herpes zoster (HZ) events in Japanese patients with moderate to severe rheumatoid arthritis enrolled in the tofacitinib clinical programme. Data included 765 patients receiving tofacitinib in Phase 2, Phase 3, and long-term extension studies. ALCs/LSCs and incidence rates (patients with events/100 patient-years) of SIEs and HZ were analysed over 75 months. Median ALCs were generally stable over 75 months of treatment. Transient numerical increases from baseline in median LSCs were observed at Month 3; LSCs were generally lower than baseline for Months 36-75. SIE/HZ incidence rates were higher in patients with ALC &lt;0.5 × 103 cells/mm3 versus those with ALC ≥0.5 × 103 cells/mm3 during tofacitinib treatment. Baseline LSCs were similar in patients with/without SIEs or HZ events. SIE/HZ risk was highest in patients with ALC &lt;0.5 × 103 cells/mm3, supporting this threshold as clinically relevant for defining increased SIE/HZ risk in Japanese patients with rheumatoid arthritis receiving tofacitinib. However, SIEs and HZ events did not necessarily occur simultaneously with confirmed lymphopenia, preventing conclusions on possible causal relationships being drawn.</description><identifier>ISSN: 1439-7595</identifier><identifier>ISSN: 1439-7609</identifier><identifier>EISSN: 1439-7609</identifier><identifier>DOI: 10.1093/mr/roae030</identifier><identifier>PMID: 38801704</identifier><language>eng</language><publisher>England</publisher><ispartof>Modern rheumatology, 2024-10, Vol.34 (6), p.1115-1124</ispartof><rights>Japan College of Rheumatology 2024. Published by Oxford University Press.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c212t-269902cc7f72951d2f51e0739f1bb222a8607b1ce7c1a00a2e30f784a42150b73</cites><orcidid>0000-0002-0807-7139 ; 0000-0002-9569-6834</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27913,27914</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38801704$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tanaka, Yoshiya</creatorcontrib><creatorcontrib>Takeuchi, Tsutomu</creatorcontrib><creatorcontrib>Valdez, Hernan</creatorcontrib><creatorcontrib>Collinge, Mark</creatorcontrib><creatorcontrib>Zwillich, Samuel H</creatorcontrib><creatorcontrib>Toyoizumi, Shigeyuki</creatorcontrib><creatorcontrib>Kwok, Kenneth</creatorcontrib><creatorcontrib>Hirose, Tomohiro</creatorcontrib><title>Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib</title><title>Modern rheumatology</title><addtitle>Mod Rheumatol</addtitle><description>We characterised changes in absolute lymphocyte counts (ALCs) and lymphocyte subset counts (LSCs), and their relationship to incidence of serious infection events (SIEs) and herpes zoster (HZ) events in Japanese patients with moderate to severe rheumatoid arthritis enrolled in the tofacitinib clinical programme. Data included 765 patients receiving tofacitinib in Phase 2, Phase 3, and long-term extension studies. ALCs/LSCs and incidence rates (patients with events/100 patient-years) of SIEs and HZ were analysed over 75 months. Median ALCs were generally stable over 75 months of treatment. Transient numerical increases from baseline in median LSCs were observed at Month 3; LSCs were generally lower than baseline for Months 36-75. SIE/HZ incidence rates were higher in patients with ALC &lt;0.5 × 103 cells/mm3 versus those with ALC ≥0.5 × 103 cells/mm3 during tofacitinib treatment. Baseline LSCs were similar in patients with/without SIEs or HZ events. SIE/HZ risk was highest in patients with ALC &lt;0.5 × 103 cells/mm3, supporting this threshold as clinically relevant for defining increased SIE/HZ risk in Japanese patients with rheumatoid arthritis receiving tofacitinib. However, SIEs and HZ events did not necessarily occur simultaneously with confirmed lymphopenia, preventing conclusions on possible causal relationships being drawn.</description><issn>1439-7595</issn><issn>1439-7609</issn><issn>1439-7609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kE1LxDAQhoMoun5c_AGSowirk6TdNEdZ_GRBED2XNJ3QaNvUJGXZi7_dyq6e5oV55mV4CDlncM1AiZsu3ASvEQTskRnLhJrLBaj9v5yr_Igcx_gBIHJVqENyJIoCmIRsRr5fsdXJ-T42bqAVpjViT9tNNzTebBJS48c-Ud3XNLj4Sb2lrrdofk-mRJ_1oHuMSEODY6eTdzXVITXBJRfpMFVjnyJNAXXCmq5damjyVptp37vqlBxY3UY8280T8n5_97Z8nK9eHp6Wt6u54YynOV8oBdwYaSVXOau5zRmCFMqyquKc62IBsmIGpWEaQHMUYGWR6YyzHCopTsjltncI_mvEmMrORYNtOz3vx1gKWDAmFM9gQq-2qAk-xoC2HILrdNiUDMpf32UXyp3vCb7Y9Y5Vh_U_-idY_ACDzX7i</recordid><startdate>20241015</startdate><enddate>20241015</enddate><creator>Tanaka, Yoshiya</creator><creator>Takeuchi, Tsutomu</creator><creator>Valdez, Hernan</creator><creator>Collinge, Mark</creator><creator>Zwillich, Samuel H</creator><creator>Toyoizumi, Shigeyuki</creator><creator>Kwok, Kenneth</creator><creator>Hirose, Tomohiro</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0807-7139</orcidid><orcidid>https://orcid.org/0000-0002-9569-6834</orcidid></search><sort><creationdate>20241015</creationdate><title>Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib</title><author>Tanaka, Yoshiya ; Takeuchi, Tsutomu ; Valdez, Hernan ; Collinge, Mark ; Zwillich, Samuel H ; Toyoizumi, Shigeyuki ; Kwok, Kenneth ; Hirose, Tomohiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c212t-269902cc7f72951d2f51e0739f1bb222a8607b1ce7c1a00a2e30f784a42150b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tanaka, Yoshiya</creatorcontrib><creatorcontrib>Takeuchi, Tsutomu</creatorcontrib><creatorcontrib>Valdez, Hernan</creatorcontrib><creatorcontrib>Collinge, Mark</creatorcontrib><creatorcontrib>Zwillich, Samuel H</creatorcontrib><creatorcontrib>Toyoizumi, Shigeyuki</creatorcontrib><creatorcontrib>Kwok, Kenneth</creatorcontrib><creatorcontrib>Hirose, Tomohiro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Modern rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanaka, Yoshiya</au><au>Takeuchi, Tsutomu</au><au>Valdez, Hernan</au><au>Collinge, Mark</au><au>Zwillich, Samuel H</au><au>Toyoizumi, Shigeyuki</au><au>Kwok, Kenneth</au><au>Hirose, Tomohiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib</atitle><jtitle>Modern rheumatology</jtitle><addtitle>Mod Rheumatol</addtitle><date>2024-10-15</date><risdate>2024</risdate><volume>34</volume><issue>6</issue><spage>1115</spage><epage>1124</epage><pages>1115-1124</pages><issn>1439-7595</issn><issn>1439-7609</issn><eissn>1439-7609</eissn><abstract>We characterised changes in absolute lymphocyte counts (ALCs) and lymphocyte subset counts (LSCs), and their relationship to incidence of serious infection events (SIEs) and herpes zoster (HZ) events in Japanese patients with moderate to severe rheumatoid arthritis enrolled in the tofacitinib clinical programme. Data included 765 patients receiving tofacitinib in Phase 2, Phase 3, and long-term extension studies. ALCs/LSCs and incidence rates (patients with events/100 patient-years) of SIEs and HZ were analysed over 75 months. Median ALCs were generally stable over 75 months of treatment. Transient numerical increases from baseline in median LSCs were observed at Month 3; LSCs were generally lower than baseline for Months 36-75. SIE/HZ incidence rates were higher in patients with ALC &lt;0.5 × 103 cells/mm3 versus those with ALC ≥0.5 × 103 cells/mm3 during tofacitinib treatment. Baseline LSCs were similar in patients with/without SIEs or HZ events. SIE/HZ risk was highest in patients with ALC &lt;0.5 × 103 cells/mm3, supporting this threshold as clinically relevant for defining increased SIE/HZ risk in Japanese patients with rheumatoid arthritis receiving tofacitinib. However, SIEs and HZ events did not necessarily occur simultaneously with confirmed lymphopenia, preventing conclusions on possible causal relationships being drawn.</abstract><cop>England</cop><pmid>38801704</pmid><doi>10.1093/mr/roae030</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-0807-7139</orcidid><orcidid>https://orcid.org/0000-0002-9569-6834</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1439-7595
ispartof Modern rheumatology, 2024-10, Vol.34 (6), p.1115-1124
issn 1439-7595
1439-7609
1439-7609
language eng
recordid cdi_proquest_miscellaneous_3061139240
source Oxford University Press Journals All Titles (1996-Current)
title Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T07%3A50%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relationship%20between%20lymphocyte%20count%20and%20risk%20of%20infection%20in%20Japanese%20rheumatoid%20arthritis%20patients%20treated%20with%20tofacitinib&rft.jtitle=Modern%20rheumatology&rft.au=Tanaka,%20Yoshiya&rft.date=2024-10-15&rft.volume=34&rft.issue=6&rft.spage=1115&rft.epage=1124&rft.pages=1115-1124&rft.issn=1439-7595&rft.eissn=1439-7609&rft_id=info:doi/10.1093/mr/roae030&rft_dat=%3Cproquest_cross%3E3061139240%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3061139240&rft_id=info:pmid/38801704&rfr_iscdi=true